XML 112 R68.htm IDEA: XBRL DOCUMENT
v3.22.4

Consolidated shareholders’ equity (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2022
Share Capital, Reserves And Other Equity Interest [Abstract] |
Summary of Treasury Shares Held | Treasury shares held by Sanofi are as follows:
| Number of shares (million) | % of share capital for the period
December 31, 2022 | 8.20 |  | 0.650 | %
December 31, 2021 | 11.02 |  | 0.872 | %
December 31, 2020 | 8.28 |  | 0.658 | %
January 1, 2020 | 0.02 |  | 0.002 | %
Summary of Movements Share Capital | Movements in the share capital of the Sanofi parent company over the last three years are set forth below:
Date | Transaction | Number of shares
December 31, 2019 |  | 1,253,846,111 |
During 2020 | Capital increase by exercise of stock subscription options(a) | 868,655 |
During 2020 | Capital increase by issuance of restricted shares(b) | 1,666,256 |
Board meeting of July 28, 2020 | Capital increase reserved for employees | 2,590,716 |
December 31, 2020 |  | 1,258,971,738 |
During 2021 | Capital increase by exercise of stock subscription options(a) | 190,076 |
During 2021 | Capital increase by issuance of restricted shares(b) | 1,836,179 |
Board meeting of July 28, 2021 | Capital increase reserved for employees | 2,562,702 |
December 31, 2021 |  | 1,263,560,695 |
During 2022 | Capital increase by exercise of stock subscription options(a) | 490,373 |
During 2022 | Capital increase by issuance of restricted shares(b) | 1,499,987 |
Board meeting of July 27, 2022 | Capital increase reserved for employees | 2,027,057 |
Board meeting of December 14, 2022 | Reduction in share capital by cancellation of treasury shares | (6,742,380) |
December 31, 2022 |  | 1,260,835,732 |
(a) Shares issued on exercise of Sanofi stock subscription options. (b) Shares vesting under restricted share plans and issued in the period.
Principal Characteristics of Restricted Share Plans | Restricted share plans are accounted for in accordance with the policies described in Note B.24.3. The principal characteristics of those plans are as follows:
| 2022 | 2021 | 2020
Type of plan | Performance share plans | Performance share plans | Performance share plans | Performance share plans | Performance share plans | Performance share plans
Date of Board meeting approving the plan | May 3, 2022 | December 14, 2022 | April 30, 2021 | October 27, 2021 | April 28, 2020 | October 28, 2020
Service period | 3 years | 3 years | 3 years | 3 years | 3 years | 3 years
Total number of shares awarded | 3,344,432 |  | 109,981 |  | 3,484,420 |  | 13,521 |  | 3,340,501 |  | 73,027 |
Of which with no market condition | 2,000,627 |  | 10,335 |  | 2,209,901 |  | — |  | 2,536,893 |  | — |
Fair value per share awarded(a) | €91.19 |  | €79.17 |  | €77.27 |  | — |  | €82.36 |  | — |
Of which with market condition | 1,343,805 |  | 99,646 |  | 1,274,519 |  | 13,521 |  | 803,608 |  | 73,027 |
Fair value per share awarded other than to the Chief Executive Officer(b) | €86.65 |  | €69.60 |  | €71.30 |  | €68.45 |  | €76.11 |  | €63.18 |
Fair value per share awarded other than to the Chief Executive Officer - additional shares(c) | €49.00 |  | €54.70 |  | — |  | — |  | — |  | — |
Fair value per share awarded to the Chief Executive Officer(b) | €84.46 |  | — |  | €71.30 |  | — |  | €76.11 |  | — |
Fair value of plan at the date of grant (€ million) | 294 |  | 8 |  | 262 |  | 1 |  | 270 |  | 5 |
(a) Market price of Sanofi shares at the date of grant, adjusted for dividends expected during the vesting period. (b) Weighting between (i) fair value determined using the Monte Carlo model and (ii) market price of Sanofi shares at the date of grant, adjusted for dividends expected during the vesting period. (c) Additional tranche subject to a higher level of market conditions: 114,874 additional shares were awarded in May 2022, and 9,066 additional shares were awarded in December 2022.
Summary of Number of Restricted Shares Not Yet Fully Vested | The total expense recognized for all restricted share plans, and the number of restricted shares not yet fully vested, are shown in the table below:
| 2022 | 2021 | 2020
Total expense for restricted share plans (€ million) | 206 |  | 193 |  | 222 |
Number of shares not yet fully vested | 9,121,573 |  | 9,507,849 |  | 10,546,612 |
Under 2022 plans | 3,206,861 |  | — |  | — |
Under 2021 plans | 3,097,531 |  | 3,364,895 |  | — |
Under 2020 plans | 2,817,181 |  | 3,014,496 |  | 3,284,558 |
Under 2019 plans | — |  | 3,128,458 |  | 3,375,717 |
Under 2018 plans | — |  | — |  | 3,886,337 |
Summary of Characteristics of Employee Share Ownership Plans Awarded | The characteristics of the employee share ownership plans awarded in the form of a capital increase reserved for employees in 2022, 2021 and 2020 are summarized in the table below:
| 2022 | 2021 | 2020
Date of Board meeting approving the plan | February 3, 2022 | February 4, 2021 | February 5, 2020
Subscription price (€)(a) | 80.21 |  | 69.38 |  | 70.67 |
Subscription period | June 9-29, 2022 | June 7-25, 2021 | June 8-26, 2020
Number of shares subscribed | 1,909,008 |  | 2,438,590 |  | 2,467,101 |
Number of shares issued immediately as employer’s contribution | 118,049 |  | 124,112 |  | 123,615 |
(a) Subscription price representing 80% of the average of the opening quoted market prices of Sanofi shares during the 20 trading days preceding June 6, 2022, June 3, 2021 and June 2, 2020, respectively.
Summary of Expenses | The table below sets forth the expense recognized for each plan:
(€ million) | 2022 | 2021 | 2020
Expense recognized | 39 |  | 51 |  | 52 |
of which employer’s contribution | 11 |  | 11 |  | 11 |
Summary of Repurchases program | The following repurchases have been made under those programs:
(in number of shares and € million) Year of authorization | 2022 | 2021 | 2020
Number of shares | Value | Number of shares | Value | Number of shares | Value
2022 program | 1,510,000 |  | 137 |  | — |  | — |  | — |  | — |
2021 program | 3,976,992 |  | 360 |  | 2,765,388 |  | 242 |  | — |  | — |
2020 program | — |  | — |  | 1,758,569 |  | 140 |  | 5,685,426 |  | 461 |
2019 program | — |  | — |  | — |  | — |  | 3,982,939 |  | 361 |
Summary of Currency Translation Differences | Currency translation differences comprise the following:
(€ million) | 2022 | 2021 |  | 2020 | (a)
Attributable to equity holders of Sanofi | 1,499 |  | (865) |  |  | (3,384) |  |
Attributable to non-controlling interests | (37) |  | (42) |  |  | (55) |  |
Total | 1,462 |  | (907) |  |  | (3,439) |  |
(a) Includes the impact of the IFRIC agenda decision of March 2021 on the costs of configuring or customising application software used in a Software as a Service (SaaS) arrangement, as described in Note A.2.1. to the financial statements for the year ended December 31, 2021.
Summary of Movements within Other Comprehensive Income | Movements within other comprehensive income are shown below:
(€ million) | 2022 | 2021 |  | 2020 | (a)
Actuarial gains/(losses): |  |  |  |  |
•Actuarial gains/(losses) excluding investments accounted for using the equity method (see Note D.19.1.) | 650 |  | 685 |  |  | (266) |  |
•Actuarial gains/(losses) of investments accounted for using the equity method, net of taxes | 4 |  | 1 |  |  | (1) |  |
•Tax effects | (212) |  | (36) |  |  | 45 |  |
Equity instruments included in financial assets and financial liabilities: |  |  |  |  |
•Change in fair value (excluding investments accounted for using the equity method) | (4) |  | 154 |  |  | 358 |  |
•Change in fair value (investments accounted for using the equity method, net of taxes) | — |  | — |  |  | (14) |  |
•Equity risk hedging instruments designated as fair value hedges | 17 |  | 11 |  |  | (24) |  |
•Tax effects | (4) |  | (18) |  |  | (84) |  |
Items not subsequently reclassifiable to profit or loss | 451 |  | 797 |  |  | 14 |  |
Debt instruments included in financial assets: |  |  |  |  |
•Change in fair value (excluding investments accounted for using the equity method)(b) | (77) |  | (21) |  |  | 15 |  |
•Tax effects | 15 |  | 5 |  |  | (3) |  |
Cash flow and fair value hedges: |  |  |  |  |
•Change in fair value (excluding investments accounted for using the equity method)(c) | 5 |  | (6) |  |  | 4 |  |
•Change in fair value (investments accounted for using the equity method, net of taxes) | 2 |  | — |  |  | — |  |
▪Tax effects | (1) |  | 2 |  |  | (2) |  |
Change in currency translation differences: |  |  |  |  |
•Currency translation differences on foreign subsidiaries (excluding investments accounted for using the equity method)(d) | 2,643 |  | 2,719 |  |  | (3,870) |  |
•Currency translation differences (investments accounted for using the equity method)(d) | (11) |  | (6) |  |  | 32 |  |
•Currency translation differences related to the investment in Regeneron and reclassified to profit or loss(e) | — |  | — |  |  | (318) |  |
•Hedges of net investments in foreign operations(d) | (354) |  | (254) |  |  | 180 |  |
•Tax effects(e) | 91 |  | 71 |  |  | (59) |  |
Items subsequently reclassifiable to profit or loss | 2,313 |  | 2,510 |  |  | (4,021) |  |
(a) Includes the impacts of the IFRIC final agenda decisions of March 2021 on the costs of configuring or customising application software used in a Software as a Service (SaaS) arrangement and of April 2021 on the attribution of benefits to periods of service, as described in Note A.2.1. to the consolidated financial statements for the year ended December 31, 2021. (b) Amounts reclassified to profit or loss: immaterial amount in 2022, €4 million in 2021 and €5 million in 2020. (c) Amounts reclassified to profit or loss: €2 million in 2022, €12 million in 2021 and €1 million in 2020. (d) Amounts reclassified to profit or loss: €40 million in 2022, including €35 million relating to the deconsolidation of EUROAPI (see note D.1.). The amounts reclassified to profit and loss were immaterial in 2021 and 2020. Currency translation differences arise from the translation into euros of the financial statements of foreign subsidiaries, and are mainly due to the appreciation of the dollar against the euro. (e) The amount recorded for 2020 relates to the translation reserve arising on the investment in Regeneron; the reserve was reclassified to profit or loss in accordance with IAS 21 (The Effects of Changes in Foreign Exchange Rates), including €2 million (net of tax) relating to hedges of net investments in foreign operations.
Disclosure of Stock Subscription Option Plan Outstanding and Option Exercised | The table shows all Sanofi stock subscription option plans still outstanding or under which options were exercised in the year ended December 31, 2022:
Source | Date of grant | Number of options granted | Start date of exercise period | Expiry date | Exercise price (€) | Number of options outstanding as of 12/31/2022
Sanofi-Aventis | 03/05/2012 | 814,050 |  | 03/06/2016 | 03/05/2022 | 56.44 |  | — |
Sanofi | 03/05/2013 | 788,725 |  | 03/06/2017 | 03/05/2023 | 72.19 |  | 78,089 |
Sanofi | 03/05/2014 | 1,009,250 |  | 03/06/2018 | 03/05/2024 | 73.48 |  | 506,042 |
Sanofi | 06/24/2015 | 435,000 |  | 06/25/2019 | 06/24/2025 | 89.38 |  | 338,464 |
Sanofi | 05/04/2016 | 402,750 |  | 05/05/2020 | 05/04/2026 | 75.90 |  | 264,750 |
Sanofi | 05/10/2017 | 378,040 |  | 05/11/2021 | 05/10/2027 | 88.97 |  | 268,440 |
Sanofi | 05/02/2018 | 220,000 |  | 05/03/2022 | 05/02/2028 | 65.84 |  | 168,784 |
Sanofi | 04/30/2019 | 220,000 |  | 05/02/2023 | 04/30/2029 | 76.71 |  | 213,400 |
Total |  |  |  |  |  | 1,837,969 |
Summary of Stock Options Outstanding at Each Balance Sheet Date | A summary of stock options outstanding at each balance sheet date, and of movements during the relevant periods, is presented below:
| Number of options | Weighted average exercise price per share (€) | Total (€ million)
Options outstanding at January 1, 2020 | 3,822,020 |  | 70.58 |  | 270 |
Options exercisable | 2,650,375 |  | 67.14 |  | 178 |
Options exercised | (868,655) |  | 59.20 |  | (52) |
Options cancelled(a) | (91,305) |  | 87.73 |  | (8) |
Options forfeited | (282,790) |  | 54.12 |  | (15) |
Options outstanding at December 31, 2020 | 2,579,270 |  | 75.61 |  | 195 |
Options exercisable | 1,845,050 |  | 74.51 |  | 137 |
Options exercised | (190,076) |  | 59.53 |  | (11) |
Options cancelled(a) | (51,216) |  | 65.84 |  | (3) |
Options forfeited | (10) |  | 50.48 |  | — |
Options outstanding at December 31, 2021 | 2,337,968 |  | 77.13 |  | 180 |
Options exercisable | 1,949,184 |  | 78.15 |  | 152 |
Options exercised | (490,373) |  | 71.39 |  | (35) |
Options cancelled(a) | (9,626) |  | 80.56 |  | (1) |
Options outstanding at December 31, 2022 | 1,837,969 |  | 78.64 |  | 145 |
Options exercisable | 1,624,569 |  | 78.89 |  | 128 |
(a) Mainly due to the grantees leaving Sanofi.
Summary of Options Outstanding and Exercisable | The table below provides summary information about options outstanding and exercisable as of December 31, 2022:
| Outstanding | Exercisable
Range of exercise prices per share | Number of options | Weighted average residual life (years) | Weighted average exercise price per share (€) | Number of options | Weighted average exercise price per share (€)
From €60.00 to €70.00 per share | 168,784 |  | 5.34 | 65.84 |  | 168,784 |  | 65.84 |
From €70.00 to €80.00 per share | 1,062,281 |  | 2.68 | 74.64 |  | 848,881 |  | 74.12 |
From €80.00 to €90.00 per share | 606,904 |  | 3.31 | 89.20 |  | 606,904 |  | 89.20 |
Total | 1,837,969 |  |  |  | 1,624,569 |  |
Summary of Number of Shares Used to Compute Diluted Earnings Per Share |
(million) | 2022 | 2021 | 2020
Average number of shares outstanding | 1,251.9 |  | 1,252.5 |  | 1,253.6 |
Adjustment for stock options with dilutive effect | 0.3 |  | 0.3 |  | 0.4 |
Adjustment for restricted shares | 4.7 |  | 5.1 |  | 6.1 |
Average number of shares used to compute diluted earnings per share | 1,256.9 |  | 1,257.9 |  | 1,260.1 |

X
- Definition Additional information about share-based payment arrangements necessary to satisfy the disclosure requirements of IFRS 2. [Refer: Share-based payment arrangements [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 2 -IssueDate 2021-01-01 -Paragraph 52 -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_52&doctype=Standard -URIDate 2021-03-24 + Details
Name: | ifrs-full_AdditionalInformationAboutSharebasedPaymentArrangements
Namespace Prefix: | ifrs-full_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition The disclosure of classes of share capital. [Refer: Share capital [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 1 -IssueDate 2021-01-01 -Paragraph 79 -Subparagraph a -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_79_a&doctype=Standard -URIDate 2021-03-24 + Details
Name: | ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition The disclosure of the general terms and conditions of share-based payment arrangements. [Refer: Share-based payment arrangements [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 2 -IssueDate 2021-01-01 -Paragraph 45 -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45&doctype=Standard -URIDate 2021-03-24 + Details
Name: | ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Disclosure of detailed information of accumulated other comprehensive income. + References No definition available. + Details
Name: | sny_DisclosureOfAccumulatedOtherComprehensiveIncomeExplanatoryTableTextBlock
Namespace Prefix: | sny_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Disclosure of employee stock ownership plan awarded in capital increase reserved explanatory [Text Block] + References No definition available. + Details
Name: | sny_DisclosureOfEmployeeStockOwnershipPlanAwardedInCapitalIncreaseReservedExplanatoryTableTextBlock
Namespace Prefix: | sny_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Disclosure of number of restricted share plans Not yet fully vested. + References No definition available. + Details
Name: | sny_DisclosureOfNumberOfRestrictedSharePlansNotYetFullyVestedTableTextBlock
Namespace Prefix: | sny_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition The disclosure of reserve of exchange differences on translation. + References No definition available. + Details
Name: | sny_DisclosureOfReserveOfExchangeDifferencesOnTranslationTableTextBlock
Namespace Prefix: | sny_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition The disclosure of share based compensation shares authorized under stock option plans by exercise price range. + References No definition available. + Details
Name: | sny_DisclosureOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock
Namespace Prefix: | sny_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Disclosure of share repurchase program explanatory. + References No definition available. + Details
Name: | sny_DisclosureOfShareRepurchaseProgramExplanatoryTableTextBlock
Namespace Prefix: | sny_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition The disclosure of shares used to compute diluted earnings per share. + References No definition available. + Details
Name: | sny_DisclosureOfSharesUsedToComputeDilutedEarningsPerShareTableTextBlock
Namespace Prefix: | sny_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition The disclosure of statement of changes in equity of parent. + References No definition available. + Details
Name: | sny_DisclosureOfStatementOfChangesInEquityOfParentTableTextBlock
Namespace Prefix: | sny_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition The disclosure of stock options outstanding at each balance sheet date and of changes during the relevant periods. + References No definition available. + Details
Name: | sny_DisclosureOfStockOptionsOutstandingAtEachBalanceSheetDateAndOfChangesDuringTheRelevantPeriodsTableTextBlock
Namespace Prefix: | sny_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition The disclosure of stock subscription option plans under which options were exercised in the year. + References No definition available. + Details
Name: | sny_DisclosureOfStockSubscriptionOptionPlansUnderWhichOptionsWereExercisedInTheYearTableTextBlock
Namespace Prefix: | sny_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Share Capital, Reserves And Other Equity Interest [Abstract] + References No definition available. + Details
Name: | sny_ShareCapitalReservesAndOtherEquityInterestAbstract
Namespace Prefix: | sny_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration